<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ssmu</journal-id><journal-title-group><journal-title xml:lang="ru">Бюллетень сибирской медицины</journal-title><trans-title-group xml:lang="en"><trans-title>Bulletin of Siberian Medicine</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1682-0363</issn><issn pub-type="epub">1819-3684</issn><publisher><publisher-name>Siberian State Medical University, the Ministry of Healthcare of the Russian Federation</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.20538/1682-0363-2019-3-72-80</article-id><article-id custom-type="elpub" pub-id-type="custom">ssmu-2402</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL PAPERS</subject></subj-group></article-categories><title-group><article-title>Разработка способа получения производного октреотида для диагностики нейроэндокринных опухолей</article-title><trans-title-group xml:lang="en"><trans-title>Development of a method for preparing octreotide derivative for diagnosis of neuroendocrine tumors</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ларькина</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Larkina</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. фарм. наук, доцент, кафедра фармацевтического анализа,</p><p>634050, г. Томск, Московский тракт, 2</p></bio><bio xml:lang="en"><p>PhD, Associate Professor, Pharmaceutical Analysis Division, </p><p>2, Moscow Trakt, Tomsk, 634050</p></bio><email xlink:type="simple">marialarkina@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Подрезова</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Podrezova</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>аспирант, кафедра технологии органических веществ и полимерных материалов,</p><p>634050, г. Томск, пр. Ленина, 30</p></bio><bio xml:lang="en"><p>Post-Graduate Student, Division of Technology of Organic Substances and Polymer Materials,</p><p>30, Lenina Av., Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Брагина</surname><given-names>О. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Bragina</surname><given-names>O. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, мл. науч. сотрудник, отделение радионуклидной диагностики,</p><p>634009, г. Томск, пер. Кооперативный, 5</p></bio><bio xml:lang="en"><p>PhD, Junior Researcher, Nuclear Medicine Department,</p><p>5, Kooperativnyi Str., Tomsk, 634009</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Тагирова</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Tagirova</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. техн. наук, инженер лаборатории № 31,</p><p>634050, г. Томск, пр. Ленина, 30</p></bio><bio xml:lang="en"><p>PhD, Engineer, Laboratory No. 31,</p><p>30, Lenina Av., Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Чернов</surname><given-names>В. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Chernov</surname><given-names>V. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р мед. наук, профессор, зам. директора по научной работе и инновационной деятельности, зав. отделением радионуклидной диагностики,</p><p>634009, г. Томск, пер. Кооперативный, 5</p></bio><bio xml:lang="en"><p>DM, Professor, Head of the Nuclear Medicine Department,</p><p>5, Kooperativnyi Str., Tomsk, 634009</p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Юсубов</surname><given-names>М. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Yusubov</surname><given-names>M. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р хим. наук, профессор, зав. кафедрой технологии органических веществ и полимерных материалов,</p><p>634050, г. Томск, пр. Ленина, 30</p></bio><bio xml:lang="en"><p>DChSc, Professor, Head of the Division of Technology of Organic Substances and Polymer Materials,</p><p>30, Lenina Av., Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Нестеров</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Nesterov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. техн. наук, науч. сотрудник, лаборатория № 31,</p><p>634050, г. Томск, пр. Ленина, 30</p></bio><bio xml:lang="en"><p>PhD, Researcher, Laboratory No. 31,</p><p>30, Lenina Av., Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Скуридин</surname><given-names>В. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Skuridin</surname><given-names>V. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р техн. наук, профессор, зав. лабораторией № 31,</p><p>634050, г. Томск, пр. Ленина, 30</p></bio><bio xml:lang="en"><p>DTSc, Professor, Head of the Laboratory No. 31,</p><p>30, Lenina Av., Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кривощеков</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Krivoshchekov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>мл. науч. сотрудник, Центральная научно-исследовательская лаборатория, 634050, г. Томск, Московский тракт, 2;</p><p>инженер, кафедра технологии органических веществ и полимерных материалов, 634050, г. Томск, пр. Ленина, 30</p></bio><bio xml:lang="en"><p>Junior Researcher, Central Research Laboratory, 2, Moscow Trakt, Tomsk, 634050;</p><p>Engineer; Division of Technology of Organic Substances and Polymer Materials, 30, Lenina Av., Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-4"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Яновская</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Yanovskaya</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. биол. наук, мл. науч. сотрудник, НИИФиРМ им. Е.Д. Гольдберга,</p><p>634028, г. Томск, пр. Ленина, 3</p></bio><bio xml:lang="en"><p>PhD, Junior Researcher,</p><p>3, Leninа Av., Tomsk, 634028</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гурто</surname><given-names>Р. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Gurto</surname><given-names>R. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>канд. мед. наук, вед. науч. сотрудник, НИИФиРМ им. Е.Д. Гольдберга,</p><p>634028, г. Томск, пр. Ленина, 3</p></bio><bio xml:lang="en"><p>PhD, Leading Researcher,</p><p>3, Leninа Av., Tomsk, 634028</p></bio><xref ref-type="aff" rid="aff-5"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Белоусов</surname><given-names>М. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Belousov</surname><given-names>M. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>д-р фарм. наук, профессор, зав. кафедрой фармацевтического анализа,</p><p>634050, г. Томск, пр. Ленина, 30</p></bio><bio xml:lang="en"><p>DPhSc, Professor, Head of the Division of Pharmaceutical Analysis,</p><p>2, Moscow Trakt, Tomsk, 634050</p></bio><xref ref-type="aff" rid="aff-6"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет (СибГМУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University (SSMU)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Национальный исследовательский Томский политехнический университет (НИ ТПУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>National Research Tomsk Polytechnic University (NR TPU)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Научно-исследовательский институт (НИИ) онкологии, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Cancer Research Institute, Tomsk National Research Medical Center (NRMC), Russian Academy of Science</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>Сибирский государственный медицинский университет (СибГМУ);&#13;
Национальный исследовательский Томский политехнический университет (НИ ТПУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University (SSMU);&#13;
National Research Tomsk Polytechnic University (NR TPU)</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-5"><aff xml:lang="ru"><institution>Научно-исследовательский институт фармакологии и регенеративной медицины (НИИФиРМ) им. Е.Д. Гольдберга, Томский национальный исследовательский медицинский центр (НИМЦ) Российской академии наук</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Goldberg Research Institute of Pharmacology and Regenerative Medicine (GRIPhRM), Tomsk National Research Medical Center (NRMC), Russian Academy of Science</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-6"><aff xml:lang="ru"><institution>Национальный исследовательский Томский политехнический университет (НИ ТПУ)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Siberian State Medical University (SSMU)</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>27</day><month>10</month><year>2019</year></pub-date><volume>18</volume><issue>3</issue><fpage>72</fpage><lpage>80</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ларькина М.С., Подрезова Е.В., Брагина О.Д., Тагирова Е.А., Чернов В.И., Юсубов М.С., Нестеров Е.А., Скуридин В.С., Кривощеков С.В., Яновская Е.А., Гурто Р.В., Белоусов М.В., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Ларькина М.С., Подрезова Е.В., Брагина О.Д., Тагирова Е.А., Чернов В.И., Юсубов М.С., Нестеров Е.А., Скуридин В.С., Кривощеков С.В., Яновская Е.А., Гурто Р.В., Белоусов М.В.</copyright-holder><copyright-holder xml:lang="en">Larkina M.S., Podrezova E.V., Bragina O.D., Tagirova E.A., Chernov V.I., Yusubov M.S., Nesterov E.A., Skuridin V.S., Krivoshchekov S.V., Yanovskaya E.A., Gurto R.V., Belousov M.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://bulletin.ssmu.ru/jour/article/view/2402">https://bulletin.ssmu.ru/jour/article/view/2402</self-uri><abstract><sec><title>Введение</title><p>Введение. В настоящее время разработка технологии мечения аналогов соматостатина технецием99м (99mTc) для радинуклидной диагностики нейроэндокринных опухолей активно проводится по всему миру. Аналоги соматостатина, к которым относится октреотид, связываются с 99mTc только путем предварительного присоединения к ним хелатирующего агента. Поэтому актуальным является модификация октреотида прекурсорами с высокой хелатирующей способностью для прочного связывания 99mTc. В качестве таких прекурсоров успешно могут применяться ω-бис(пиридин-2- илметил)амино)алифатические кислоты.</p></sec><sec><title>Цель исследования</title><p>Цель исследования. Разработка способа получения нового производного октреотида, пригодного для диагностики нейроýндокринных опухолей.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. В качестве объекта исследования использовали октреотид – аналог соматостатина. В качестве бифункционального хелатирующего агента использовали сукцинимид-1-ил 6-(бис(пиридин-2-илметил)амино)гексаноат, синтезированный по модифицированной методике с учетом специфики агента. Для разделения и анализа синтезированных соединений применяли методы высокоýффективной жидкостной хроматографии и масс-спектрометрии.</p></sec><sec><title>Результаты исследования</title><p>Результаты исследования. Предложен способ получения производного октреотида с применением хелатирующего агента сукцинимид-1-ил 6-(бис(пиридин-2-илметил)амино)гексаноата в среде 10 ммоль PBS (рН = 6,0) с добавлением 20%-го ацетонитрила в течение 24 ч. Разработаны условия для анализа и очистки активного производного октреотида с использованием аналитической и полупрепаративной жидкостной хроматографии.</p></sec><sec><title>Заключение</title><p>Заключение. Впервые в результате модификации октреотида по остатку D-фенилаланина создан центр хелатирования для технеция-99м на основе ω-бис(пиридин-2-илметил)амино)алифатических кислот. Производное октреотида является перспективным для дальнейшего изучения его функциональной пригодности для диагностики нейроэндокринных опухолей. </p></sec></abstract><trans-abstract xml:lang="en"><p>Currently the development of technologies for labeling somatostatin with technetium-99m for diagnosing radionuclide neuroendocrine tumors is under way. Somatostatin analogues are binded with technetium99m only by the preliminary addition of a chelating agent. Therefore, it is important to develop a method for preparation of an octreotide derivative by modifying octreotide with precursors: ligands with high chelating ability for its tight binding with technetium-99m. ω-Bis(pyridin-2-ylmethyl)amino)aliphatic acids can be used successfully as such precursors.</p><p>The purpose of the study was to develop a method for obtaining a new octreotide derivative for diagnosing neuroendocrine tumors.</p><sec><title>Materials and methods</title><p>Materials and methods. The somatostatin octreotide analogue was used as the object of the study; succinimid-1-yl 6-(bis(pyridin-2-ylmethyl)amino)hexanoate was used as a chelating agent. Methods of high performance liquid chromatography and mass spectrometry were used to separate and analyze the synthesized compounds.</p></sec><sec><title>Results</title><p>Results. A method to produce an original octreotide derivative using a succinimid-1-yl 6-(bis(pyridin2-ylmethyl)amino)hexanoate as a chelating agent was proposed. The conditions of analytical and semipreparative HPLC for the analysis and purification of the active octreotide derivative (a monosubstituted derivative of the amino acid residue of D-phenylalanine) were suggested.</p></sec><sec><title>Conclusion</title><p>Conclusion. The synthesized derivative of octreotide has a chelating center for strong binding to technetium-99m in its structure, which can be useful for diagnosing neuroendocrine tumors. </p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>октреотид</kwd><kwd>технеций-99м</kwd><kwd>хелатирующий агент</kwd><kwd>соматостатиновые рецепторы</kwd><kwd>нейроэндокринные опухоли</kwd><kwd>ОФЭКТ</kwd></kwd-group><kwd-group xml:lang="en"><kwd>octreotide</kwd><kwd>technetium-99m</kwd><kwd>chelating agent</kwd><kwd>somatostatin receptors</kwd><kwd>neuroendocrine tumors</kwd><kwd>SPECT</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Sundin A., Rockall A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. Neuroendocrinology. 2012; 96 (4): 261–271. DOI: 10.1159/000342270.</mixed-citation><mixed-citation xml:lang="en">Sundin A., Rockall A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: the challenges ahead. Neuroendocrinology. 2012; 96 (4): 261–271. DOI: 10.1159/000342270.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Oberg K.E., Reubi J.C., Kwekkeboom D.J. et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010; 139 (3): 742–753. DOI: 10.1053/j.gastro.2010.07.002.</mixed-citation><mixed-citation xml:lang="en">Oberg K.E., Reubi J.C., Kwekkeboom D.J. et al. Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology. 2010; 139 (3): 742–753. DOI: 10.1053/j.gastro.2010.07.002.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Eads J.R., Meropol N.J. A New Era for the Systemic Therapy of Neuroendocrine Tumors. The Oncologist. 2012; 17 (3): 326–338. DOI: 10.1634/theoncologist.2011-0356.</mixed-citation><mixed-citation xml:lang="en">Eads J.R., Meropol N.J. A New Era for the Systemic Therapy of Neuroendocrine Tumors. The Oncologist. 2012; 17 (3): 326–338. DOI: 10.1634/theoncologist.2011-0356.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Strosberg J.R., Fine R.L., Choi J. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011; 117: 268–275. DOI: 10.1002/cncr.25425.</mixed-citation><mixed-citation xml:lang="en">Strosberg J.R., Fine R.L., Choi J. et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer. 2011; 117: 268–275. DOI: 10.1002/cncr.25425.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Чернов В.И., Брагина О.Д., Синилкин И.Г., Медведева А.А., Çельчан Р.В. Радионуклидная тераностика злокачественных образований. Вестник рентгенологии и радиологии. 2016; 97 (5): 306–313.</mixed-citation><mixed-citation xml:lang="en">Chernov V.I., Bragina O.D., Sinilkin I.G. et al. Radioimmunotherapy: current state of the problem. Vestnik Rentgenologii and Radiologii. 2016; 62 (1): 24–30 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Чернов В.И., Брагина О.Д., Синилкин И.Г., Медведева А.А., Çельчан Р.В. Радиоиммунотерапия: современное состояние проблемы. Вопросы онкологии. 2016; 62 (1): 24–30.</mixed-citation><mixed-citation xml:lang="en">Chernov V.I., Bragina O.D., Sinilkin I.G. et al. Radioimmunotherapy in the treatment of malignancies. Questions of Оncology. 2016; 15 (2): 101–106 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Чернов В.И., Брагина О.Д., Синилкин И.Г., Медведева А.А., Çельчан Р.В. Радиоиммунотерапия в лечении злокачественных образований. Сибирский онкологический журнал. 2016; 15 (2): 101–106.</mixed-citation><mixed-citation xml:lang="en">Chernov V.I., Bragina O.D., Sinilkin I.G. et al. Radioimmunotherapy in treatment of malignancies. Siber. J. Oncol. 2016; 97 (5): 306–313 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Kwekkeboom D.J., Boen L.K., Martijn E. et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer. 2010; 17 (1): R53–73. DOI: 10.1677/ERC-09-0078.</mixed-citation><mixed-citation xml:lang="en">Kwekkeboom D.J., Boen L.K., Martijn E. et al. Somatostatin receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr. Relat. Cancer. 2010; 17 (1): R53–73. DOI: 10.1677/ERC-09-0078.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Kulke M.H., Siu L.L., Tepper J.E. et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol. 2011; 29 (7): 934–943. DOI: 10.1200/JCO.2010.33.2056.</mixed-citation><mixed-citation xml:lang="en">Kulke M.H., Siu L.L., Tepper J.E. et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J. Clin. Oncol. 2011; 29 (7): 934–943. DOI: 10.1200/JCO.2010.33.2056.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mikołajczak R., Maecke H.R. Radiopharmaceuticals for somatostatin receptor imaging. Nuclear Medicine Review. 2016; 19 (2): 126–132. DOI: 10.5603/NMR.2016.0024.</mixed-citation><mixed-citation xml:lang="en">Mikołajczak R., Maecke H.R. Radiopharmaceuticals for somatostatin receptor imaging. Nuclear Medicine Review. 2016; 19 (2): 126–132. DOI: 10.5603/NMR.2016.0024.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Krenning E.P., Kwekkeboom D.J., Bakker W.H. et al. Somatostatin receptor scintigraphy with [111-InDTPA-D-Phe] and [123-I-tyr]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993; 20 (8): 716–731.</mixed-citation><mixed-citation xml:lang="en">Krenning E.P., Kwekkeboom D.J., Bakker W.H. et al. Somatostatin receptor scintigraphy with [111-InDTPA-D-Phe] and [123-I-tyr]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 1993; 20 (8): 716–731.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Kunikowska J., Krґolicki L., Hubalewska-Dydejczyk A., Mikolajczak R. et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging. 2011; 38 (10): 1788–1797. DOI: 10.1007/s00259-011-1833-x.</mixed-citation><mixed-citation xml:lang="en">Kunikowska J., Krґolicki L., Hubalewska-Dydejczyk A., Mikolajczak R. et al. Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option? Eur. J. Nucl. Med. Mol. Imaging. 2011; 38 (10): 1788–1797. DOI: 10.1007/s00259-011-1833-x.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Kwekkeboom D.J., De Herder W.W., Kam B.L. et al. Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 2008; 26 (13): 2124–2130. DOI: 10.1200/JCO.2007.15.2553.</mixed-citation><mixed-citation xml:lang="en">Kwekkeboom D.J., De Herder W.W., Kam B.L. et al. Treatment with the radiolabeled somatostatin analog [177Lu- DOTA0, Tyr3]octreotate: toxicity, efficacy, and survival. J. Clin. Oncol. 2008; 26 (13): 2124–2130. DOI: 10.1200/JCO.2007.15.2553.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Makris G., Radford L., Gallazzi F. et аl. Synthesis and evaluation of fac-[ 99mTc/Re(CO)3] þ complexes with a new (N,S,N) bifunctional chelating agent: The first example of a fac- [Re(CO)3(N,S,N-sst2-ANT)] complex bearing a somatostatin receptor antagonist peptide. Journal of Organometallic Chemistry. 2016; 805: 100–107. DOI: 10.1016/j.jorganchem.2016.01.005.</mixed-citation><mixed-citation xml:lang="en">Makris G., Radford L., Gallazzi F. et аl. Synthesis and evaluation of fac-[ 99mTc/Re(CO)3] þ complexes with a new (N,S,N) bifunctional chelating agent: The first example of a fac- [Re(CO)3(N,S,N-sst2-ANT)] complex bearing a somatostatin receptor antagonist peptide. Journal of Organometallic Chemistry. 2016; 805: 100–107. DOI: 10.1016/j.jorganchem.2016.01.005.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Zhao R., Wang J. et аl. Efficacy of 99mTc-EDDA/HYNIC-TOC SPECT/CT scintigraphy in Graves’ ophthalmopathy. Am. J. Nucl. Med. Mol. Imaging. 2012; 2 (2): 242–247.</mixed-citation><mixed-citation xml:lang="en">Zhao R., Wang J. et аl. Efficacy of 99mTc-EDDA/HYNIC-TOC SPECT/CT scintigraphy in Graves’ ophthalmopathy. Am. J. Nucl. Med. Mol. Imaging. 2012; 2 (2): 242–247.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Wild D., Macke H.R., Waser B. et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (6): 724. DOI: 10.1007/s00259-004-1697-4.</mixed-citation><mixed-citation xml:lang="en">Wild D., Macke H.R., Waser B. et al. 68Ga-DOTANOC: a first compound for PET imaging with high affinity for somatostatin receptor subtypes 2 and 5. Eur. J. Nucl. Med. Mol. Imaging. 2005; 32 (6): 724. DOI: 10.1007/s00259-004-1697-4.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Чернов В.И., Брагина О.Д., Зельчан Р.В. и др. Меченые аналоги соматостатина в тераностике нейроэндокринных опухолей. Медицинская радиология и радиационная безопасность. 2017; 3: 42–49.</mixed-citation><mixed-citation xml:lang="en">Chernov V.I., Bragina O.D., Zelchan R.V. et al. Labeled somatostatin analogues in theranostics of neuroendocrine tumors. Medical Radiology and Radiation Safety. 2017; 3: 42–49 (in Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Behera A., De K., Chandra S. Synthesis, radiolabelling and biodistribution of HYNIC-Tyr3octreotide: a somatostatin receptor positive tumour imaging agent. J. Radioanal. Nucl. Chem. 2011; 290: 123–129. DOI: 10.1007/s10967-011-1156-1.</mixed-citation><mixed-citation xml:lang="en">Behera A., De K., Chandra S. Synthesis, radiolabelling and biodistribution of HYNIC-Tyr3octreotide: a somatostatin receptor positive tumour imaging agent. J. Radioanal. Nucl. Chem. 2011; 290: 123–129. DOI: 10.1007/s10967-011-1156-1.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Skuridin V., Stasyuk E., Bragina O., Yusubov M., Chernov V., Larkina M., Zelchan R., Rogov A., Sinilkin I., Larionova L. Development of radiopharmaceutical based on mini-antibody for early cancer detection. Annual Congress of the European Association of Nuclear Medicine. Spain, Barcelona, October 15–19, 2016; 43: 465.</mixed-citation><mixed-citation xml:lang="en">Skuridin V., Stasyuk E., Bragina O., Yusubov M., Chernov V., Larkina M., Zelchan R., Rogov A., Sinilkin I., Larionova L. Development of radiopharmaceutical based on mini-antibody for early cancer detection. Annual Congress of the European Association of Nuclear Medicine. Spain, Barcelona, October 15–19, 2016; 43: 465.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Sundararajan C., Besanger T.R., Labiris R. et al. Synthesis and сharacterization of rhenium and technetium-99m labeled insulin. J. Med. Chem. 2010; 53 (6): 2612–2621. DOI: 10.1021/jm100096c.</mixed-citation><mixed-citation xml:lang="en">Sundararajan C., Besanger T.R., Labiris R. et al. Synthesis and сharacterization of rhenium and technetium-99m labeled insulin. J. Med. Chem. 2010; 53 (6): 2612–2621. DOI: 10.1021/jm100096c.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
